



ACERH

AUSTRALIAN CENTRE FOR ECONOMIC RESEARCH ON HEALTH

SEMINAR

Friday, 19 March 2010, 11:00am-12:00noon

ES Meyers Lecture Theatre
1st floor, Mayne Medical School Building
University of Queensland
Herston Road, Herston

The impact of chronic hepatitis B in Australia: Projecting mortality, morbidity and economic impact

**Professor Jim Butler, ACERH ANU, and
Dr Rosemary Korda, ACERH and NCEPH, ANU**

The Speakers

Jim Butler is Professor and Director of ACERH. He holds a PhD in economics from the University of Queensland and is based at The Australian National University. He was President of the Australian Health Economics Society from 2001 to 2005. He is currently a member of the Australian Government's Medical Services Advisory Committee (MSAC) and is Chair of the Economics Sub-Committee of MSAC. Rosemary Korda holds a joint appointment as a Research Fellow at ACERH and the National Centre for Epidemiology and Population Health, ANU. She is a member of the ACT Health Council. In 2009 she was awarded the J G Crawford Prize at ANU for her PhD thesis 'Socioeconomic inequalities in health care in Australia: Differential impacts on mortality and inequalities in the use of services'.

Abstract

Infection with hepatitis B virus (HBV) leads to a range of health outcomes ranging from spontaneous clearance of the virus without medical intervention through to death from hepatitis-related liver cancer. This seminar summarises the results of a study reported in ACERH Research Report No.7, which provides projections of the epidemiological and economic burden associated with HBV infection in Australia for the 10-year period 2008 to 2017. It also provides an assessment of the cost-effectiveness of enhancing the management and treatment of HBV infection to bring greater numbers of people infected with the virus into treatment. The Report suggests that this strategy is cost-effective and that investment in a National Strategy for Hepatitis B is economically justified. This study has received financial support from an unrestricted grant made by Bristol-Myers Squibb to the 'Advancing the Clinical Treatment of Hepatitis B Virus' (ACT-HBV) Australia initiative.

Enquiries

For enquiries about this seminar contact Ms Katherine Green (kgreen2@uq.edu.au; 07 3365 5560) or Professor Luke Connelly (l.connolly@uq.edu.au; 07 3346 4838)